

succeeding business day to make a response or take action, pursuant to 35 U.S. §21.

In the claims

Please cancel claims 22-33 and claim 38 without prejudice.

Please amend claims 1-4 as set forth below. A marked up version of the claims is provided as an Appendix.

1. (Thrice Amended) A composition for use in treating epithelial lesions formed of a combination of ingredients comprising:
- 8-hydroxyquinoline in an amount of at least five percent of the composition by weight;
 - an escharotic chelatable metal agent bonded to said 8-hydroxyquinoline including a metal having an oxidation state of +2 present in a concentration of at least five percent by weight of the composition and less than an amount that produces an eschar in healthy mammalian tissues; and
 - a carrier,
- the composition having a capacity for treating at least one type of lesion selected from the group consisting of venereal warts, male veruoca warts, lesions produced by the human papilloma virus, basal cell carcinoma, solar keratosis, Kaposi's sarcoma, eye cancer, sarcoids, sarcoma, malignant melanoma, rectal adenoma, histocytoma, sebaceous adenoma, lung cancer, breast cancer, and colon cancer.

2. (Amended) The composition as set forth in claim 1 including a ratio of 8-hydroxyquinoline to said escharotic chelatable metal agent ranging from 1:1 to 1:3 by weight.

3. (Twice Amended) The composition as set forth in claim 2 wherein said ratio is about 1:2.

4. (Twice Amended) The composition as set forth in claim 1 wherein said escharotic chelatable metal agent comprises zinc.

5. The composition as set forth in claim 1 wherein said escharotic chelatable metal agent comprises zinc chloride in an amount up to forty percent by weight of said composition by weight.

6. The composition as set forth in claim 1 wherein said escharotic chelatable metal agent comprises zinc chloride in an amount ranging up to twenty percent.

7. The composition as set forth in claim 1 in combination with necrotic tissue from lesions of said group produced by the action of said composition upon said necrotic tissue.

8. Cancelled.

9. Cancelled.

10. Cancelled.

11. Cancelled.

12. Cancelled.

13. Cancelled.

14. The composition as set forth in claim 1, wherein said carrier is a gel base.

15. The composition as set forth in claim 14 wherein said gel base is a polyoxyalkylene ether derivative of propylene glycol.

16. The composition as set forth in claim 1 wherein said carrier contains a penetrant.

17. The composition as set forth in claim 1 wherein said penetrant is lecithin.

18. The composition as set forth in claim 1 wherein said penetrant is dimethyl sulfoxide.

19. The composition as set forth in claim 1 wherein said carrier contains an antioxidant.

20. The composition as set forth in claim 19 wherein said antioxidant is selected from the group consisting of nordihydroguaiaretic acid, nordihydroguaiaretic acid derivatives, and functional homologues of nordihydroguaiaretic acid.

21. The composition as set forth in claim 19 wherein said antioxidant is selected from a group consisting of ascorbic acid, ascorbic acid derivatives, and functional homologues of ascorbic acid.

22. Canceled

23. Canceled

24. Canceled

25. Canceled